Table 1

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–2016¹

Gisele Peirano², Tarah Lynch², Yasufumi Matsumara², Diego Nobrega, Thomas J. Finn, Rebekah DeVinney, and Johann D.D. Pitout

Author affiliations: University of Calgary Cummings School of Medicine, Calgary, Alberta, Canada (G. Peirano, T. Lynch, T.J. Finn, R. De Vinney, J.D.D. Pitout); Alberta Precision Laboratories, Calgary (G. Peirano, T. Lynch, J.D.D. Pitout); Kyoto University Graduate School of Medicine, Kyoto, Japan (Y. Matsumara); University of Calgary, Calgary (D. Nobrega); University of Pretoria, Pretoria, South Africa (J.D.D. Pitout)

Main Article

Patient characteristics associated with Escherichia coli sequence type 131 clades, Calgary, Alberta, Canada, 2006–2016*

Characteristic	Clade
Characteristic	A, n = 34	B, n = 32	C0, n = 5	C1-nonM27, n = 121	C1-M27, n = 13	C2, n = 139	All, n = 344
Year
2006	0^a	14 (44)^b,c	5 (100)^b	24 (20)^c	1 (8)^a,c	9 (7)^a	53 (15)
2012	18 (53)	9 (28)	0	56 (46)	4 (31)	63 (45)	150 (44)
2016	16 (47)	9 (28)	0	41 (34)	8 (34)	67 (48)	141 (41)
Sex
M	14 (41)	10 (31)	3 (60)	59 (49)	9 (69)	76 (55)	171 (50)
F	20 (59)	22 (69)	2 (40)	62 (57)	4 (31)	63 (45)	173 (50)
Mean age, y (range)	52.9 (1–87)	66 (8–103)	72 (57–79)	67.8 (1–95)	73.1 (45–92)	67.8 (9–94)
Clinical infection
Primary sepsis	13 (38)^a	9 (28)	4 (80)^a	15 (12)^b	6 (46)	22 (16)	69 (20)
Urinary tract	15 (44)	14 (44)	1 (20)	66 (55)	6 (46)	84 (84)	186 (54)
Acute biliary	2 (6)	1 (3)	0	17 (1)	1 (8%)	10 (7)	31 (9)
Intraabdominal	3 (9)	4 (1)	0	7 (6)	0	9 (7)	23 (7)
Pneumonia	1 (3)	4 (13)	0	16 (13)	0	14 (10)	35 (10)
Origin of infection
Community-acquired	16 (47)	23 (72)^a	4 (8)	31 (26)^b	4 (31)	40 (29)^b	118 (34)
Healthcare-associated	11 (32)	7 (22)^a	0	70 (58)^b	9 (69)	69 (50)	166 (48)
Hospital-acquired	7 (21)	2 (6)	1 (20)	20 (16)	0	30 (21)	60 (18)
Not susceptible
AMC	4 (12)^a	5 (16)^a	0^a	34 (28)^a	0^a	85 (61)^b	128 (37)
TZP	0	0	0	7 (6)	0	15 (11)	22 (6)
CRO	4 (12)^a,b	1 (3)^b	0^a,b,d	40 (33)^a,d	7 (54)^c,d	94 (68)^c	146 (42)
ERT/MEM	0	0	0	0	0	1 (1)	1 (0.3)
CIP	5 (1)^a	0^a	1 (20)^a	121 (100)^b	13 (100)^b	139 (100)^b	279 (81)
SXT	22 (65)	13 (41)	3 (60)	70 (58)	6 (46)	67 (48)	181 (53)
GEN	11 (32)	8 (25)	0	59 (49)^a	0^b	62 (45)^a	140 (41)
TOB	10 (29)^a,b	7 (22)^a,b	0^a,b	53 (44)^a	0^b	86 (62)^c	156 (45)
AMK	0	0	0	0	0	1 (1)	1 (0.3)
Resistance score, median (range)†	1^a,b (0–4)	1^b (0–4)	1^a,b (0–1)	3^c (1–5)	2^a,c (1–3)	4^d (1–5)
Serotype
O16:H5	34 (100)^a	0^b	0^b	0^b	0^b	0^b	34 (10)
O25:H4	0^a	31 (97)^b	5 (100)^b	121 (100)^b	13 (100)^b	139 (100)^b	309 (90)
O2H4	0	1 (3)	0	0	0	0	1 (0.3)
fimH
41	33 (97)^a	0^b	0^b	0^b	0^b	0^b	33 (10)
89	1 (3)	0	0	0	0	0	1 (0.3)
22	0^a	15 (47)^b	0	0^a	0^a	0^a	15 (4)
27	0^a	12 (38)^b	0	0^a	0^a	0^a	12 (3)
324	0	1 (3)	0	0	0	0	1 (0.)
30	0^a	4 (13)^a	5 (100)^b	121 (100)^b	13 (100)^b	139 (100)^b	282 (82)
Plasmid type
Col (B551)	0	0	0	17 (14)	3 (23)	21 (15)	41 (12)
Col (MG828)	0	0	0	3 (2)	1 (8)	13 (9)	17 (8)
Col156	0^a	8 (25)^b	0	2 (2)^a	1 (8%)	22 (16)^b	33 (10)
Col8282	0	0	0	0	0	1 (1)	1 (0.3)
FIA	8 (32)^a,b	1 (3)^a	4 (80)^b,c	110 (91)^c	13 (100)^c	125 (90)^c	261 (76)
FIB	33 (97)^a	28 (88)	4 (80)	102 (84)^a	12 (92)	98 (71)^b	277 (81)
FIC	1 (3)	7 (22)	0	6 (5)	0	35 (25)	49 (14)
FII	26 (76)	10 (31)	3 (60)	23 (19)	1 (3)	83 (60)	146 (42)
IncI1	3 (9)	2 (6)	1 (20)	16 (13)	1 (3)	8 (6)	31 (9)
IncN	1 (3)	1 (3)	1 (20)	6 (5)	1 (3)	7 (5)	17 (5)
IncX1	0	2 (6)	0	2 (2)	0	1 (1)	5 (1)
IncX4	1 (3)	1 (3)	0	6 (5)	2 (15)	9 (6)	19 (6)
IncY	0	0	0	0	0	7 (5)	7 (2)
IncF replicons
FII_1	6 (18)^a	8 (25)^a	0^a	92 (76)^b	12 (92)^b	16 (12)^a	134 (39)
FII_2	5 (15)^a	1 (3)^a,c	0^a,c	105 (87)^b	13 (100)^b	2 (1)^c	126 (37)
FIB_20	6 (1)^a,c	1 (3)^a,b	3 (60)^c,d	97 (80)^d	11 (85)^d	2 (1)^b	120 (35)
FII_2	1 (3)^a	8 (25)^b	1 (20)	19 (16)^a,b	1 (8)^a,b	63 (45)^c	93 (27)
FIA_1	3 (9)^a	0^a	4 (80)^b	2 (2)^a	0^a	69 (50)^b	78 (23)
Grouped plasmids
Group 1	5 (15)^a	1 (3)^a,b	0^a,b	80 (66)^c	11 (85)^c	0^b	98 (28)
Group 2	0^a	0^a	1 (20)	0^a	0^a	56 (40)^b	57 (17)

*Values are no. (%) unless indicated otherwise. Not susceptible include intermediate or resistant rates. Rates followed by different superscript letters indicate significant differences between clades at the 5% level (adjusted for multiple comparisons). Group 1 plasmids: combination of FIA_1, FII_2, and FIB_20. Group 2 plasmids: combination of FII_2 and FIA_1. AMC, amoxicillin/clavulanate; AMK, amikacin; CIP, ciprofloxacin; CRO, ceftriaxone; ERT, ertapenem; GEN, gentamicin; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; TOB, tobramycin; TZP, piperacillin/tazobactam. †The resistance score was the number of antimicrobial drug classes to which resistance was detected.

Main Article

¹Accepted as an oral presentation for the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 18–21, 2020.

²These authors contributed equally to this article.

Page created: August 05, 2020

Page updated: November 19, 2020

Page reviewed: November 19, 2020

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Volume 26, Number 12—December 2020

Research

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–20161

Table 1

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–2016¹